Search academic texts

Information × Registration Number 0213U003065, 0110U000054 , R & D reports Title The improvnq of the treatment of chronic HCV-infection on the basis of studies of basic pathogenesis. popup.stage_title Head Fedorchenko Serhiy Valeriyovych, Registration Date 21-01-2013 Organization The L.V.Gromaschevskyi Scientific and Research Institute of Epidemiology and Infectious Diseases popup.description2 3. The object of study- patients with chronic hepatitis and cirrhosis. Methods - epidem iological, cnnical, serological, biochemical immunological, morphological, morphometric, statistics, information. The aim -to iмргоvе treatment of chronic HCV-infection on the basis of the studу of Ьаsiс раthоgеnesis. Studied biopsy material obtained from 52 patients with CHC. It is shown that the degree of livег fibrоsis correlated with disease duration, age of patients and sеvегаl other factors. Itis shown the interaction between the degree of hepatic steatosis the level of viremia, genotype of the virus and the presence of comorbidity. Rеvisеd 118 outpatients and patients' case histories of patients who гесived апtivirаl thеrapy (recombinant lFN monotherapyand combination therapy with IFM + ribavirin, PEG IFN + ribavirin). Estimated tolerability and toxicity of the therapy. Concludes that the most еffесtive is the combination of Peg IFN + ribavirin, calculated per kg body weight and lasts from 6 to12 months depending on the genotype of the virus. lt is shown that the disappearance of Ig Manti-HCV during the 1-st weeks of treatment is а роsitivе predict factor асhiеvе sustained virological response. It is shown that the probability of sc was determined in 12.4% of subjects in the 7.0% was diagnosed HPR anti-HCV. The main factors which contribute to spontaneous clearance are: younger age, female sеx, presence of acute hepatitis C, absence co-infection HlV and presence antibody to HBV. Maintenance dose peg-interferori used for a long time, well tolerated by patients with chronic hepatitis С and compensated cirrhosis, slow speed of the infectious process and postpone the dеvelормеnt оf lifеthrеаtеring complications. Product Description popup.authors Карюк Ж.О. Клименко Ж.Б. Ляшко О.В. Резник В.А. Соляник І.В. Федорченко С.В. Янченко В.І. popup.nrat_date 2020-04-02 Close